Key result
Clopidogrel carries similar ischemic and bleeding risks to ticagrelor in CYP2C19 loss-of-function ACS patients post-PCI.
Why the study?
The selection of P2Y12 inhibitors for acute coronary syndrome patients after PCI remains controversial among East Asian patients.
Does ticagrelor compared to clopidogrel reduce ischemic events in East Asian ACS patients with CYP2C19 loss-of-function alleles after PCI?
Cohort (n=8,683)
Does ticagrelor compared to clopidogrel reduce ischemic events in East Asian ACS patients with CYP2C19 loss-of-function alleles after PCI?
In East Asian ACS patients with CYP2C19 loss-of-function alleles post-PCI, ticagrelor and clopidogrel showed comparable risks of ischemic and bleeding events.
Answers are grounded in this paper and cite their sources.
Comparable risks support cautious clopidogrel consideration in this East Asian cohort; leaves open randomized confirmation of genotype-guided P2Y12 selection post-PCI.
Background: The selection of P2Y12 inhibitors for acute coronary syndrome patients after percutaneous coronary intervention (PCI) remains controversial among East Asian patients. Objectives: loss-of-function (LOF) alleles based on the Global Registry of Acute Coronary Events (GRACE) score. Methods: Between March 2016 and March 2019, a cohort of 8683 patients diagnosed with acute coronary syndrome who survived PCI were enrolled in this study. All patients carried the LOF allele and could calculate GRACE scores. The primary outcome was ischemic events (cardiac death, nonfatal myocardial infarction, and ischemic stroke) within 12 months. Secondary outcomes included the components of the primary outcome, all-cause mortality, Bleeding Academic Research Consortium (BARC) types 2, 3, and 5 bleeding events, and BARC types 3 and 5 bleeding events. The propensity score matching method was used to balance the baseline characteristics of patients. The Kaplan-Meier/log-rank test was adopted for the result analysis, and Cox regression was employed for adjusting for confounding factors. Conclusion: LOF alleles suggest that GRACE risk stratification may help differentiate ischemic and bleeding risks post-PCI.
No takes yet. Share an insight, caveat, or question.
Dang et al. (2025) conducted a cohort in Acute coronary syndrome (n=8,683). Ticagrelor vs. Clopidogrel was evaluated on Ischemic events (cardiac death, nonfatal myocardial infarction, and ischemic stroke) within 12 months (p=.026). In ACS patients with CYP2C19 loss-of-function alleles post-PCI, the risk of ischemic events or bleeding was comparable between clopidogrel and ticagrelor treatment groups.
Synapse has enriched 10 related papers. Consider them for comparative context: